There’s a need to propel and reinvigorate the current state of drug discovery pipeline in tackling pressing neurodegenerative disorders such as Alzheimer’s disease (AD), Lewy body dementia, Parkinson’s disease, frontotemporal dementia (FTD), and other diseases that cause dementia.
Dr. Brigid Ryan, a neuroscientist at the Centre for Brain Research at the University of Auckland, investigates neurodegenerative disease by taking a multidisciplinary approach in defining early biomarkers of dementia.
For research use only. Not for use in diagnostic procedures.
Research spotlight interview: the role of biomarkers in drug discovery for neurodegenerative disease